Cost-Effectiveness of Smoking Cessation Among Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer
In this cost-effectiveness analysis, there was robust evidence supporting the cost-effectiveness of MAPS (vs ST) at month 12 and moderate evidence at month 18 in terms of incremental cost per quit. The attenuation of intervention outcome over time was more pronounced among participants with less than 4 sessions of MAPS.
Authors
- Xiaoyu Liu (ORCID: https://orcid.org/0009-0008-6210-6288)
- Damon J. Vidrine (ORCID: https://orcid.org/0000-0002-8711-796X)
- Steven K. Sutton (ORCID: https://orcid.org/0000-0002-2504-7601)
- Sarah Jones (ORCID: https://orcid.org/0000-0001-5513-2527)
- Ya-chen Tina Shih
- David W. Wetter
- Jennifer I. Vidrine
Institutions
- University of California, Los Angeles (US)
- University of South Florida (US)
- Huntsman Cancer Institute (US)
- Moffitt Cancer Center (US)
- USC Norris Comprehensive Cancer Center (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.1543
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi
- National Institutes of Health
- National Cancer Institute